Effects of therapy on plasma-high-density-lipoprotein-cholesterol concentration in diabetes mellitus.
In 122 diabetic patients there was a signnificant inverse correlation between plasma-high-density-lipoprotein (H.D.L.)-Cholesterol concentrations and glycosylated haemoglobin concentrations. In an insulin-treated subgroup improvement in diabetic control, confirmed by a decrease in glycosylated haemoglobin concentrations, was accompanied by a significant rise in plasma-H.D.L.-cholesterol concentration. This result suggests that improved diabetic control may diminish the risk of premature ischaemic heart-disease. When three groups of patients on different treatments were matched for age, sex, weight, and diabetic control, diabetic patients receiving sulphonylureas had significantly lower plasma-H.D.L.-cholesterol concentrations than those receiving insulin or on diet alone, or non-diabetic controls. This association suggests that sulphonyl-urea administration may constitute a positive risk factor for ischaemic heart-disease in diabetic patients.
D000293:Adolescent; D000328:Adult; D002784:Cholesterol / Q000097:blood*; D003327:Coronary Disease / Q000209:etiology; D003920:Diabetes Mellitus / Q000097:blood* / Q000628:therapy; D003925:Diabetic Angiopathies / Q000209:etiology; D003927:Diet, Diabetic; D005260:Female; D006441:Hemoglobin A / Q000032:analysis; D006801:Humans; D007009:Hypolipoproteinemias / Q000139:chemically induced; D007328:Insulin / Q000627:therapeutic use; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012306:Risk; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use
D007328:Insulin; D008075:Lipoproteins, HDL; D013453:Sulfonylurea Compounds; D006441:Hemoglobin A; D002784:Cholesterol